Market News
Stay updated with the latest market trends, earnings, and economic indicators.
SBI MF, Nippon India MF buy Rs 272 crore worth Pine Labs shares; ICICI Pru MF acquire 1.5% stake in Indoco Remedies
SBI Mutual Fund through SBI Midcap Fund held 5.24 percent stake in Pine Labs, the point of sale and payment systems provider, as of March 2026.
Neutral Lupin; target of Rs 2520: Motilal Oswal
Motilal Oswal recommended Neutral rating on Lupin with a target price of Rs 2520 in its research report dated May 10, 2026.
Max Healthcare shares fall up to 7% as Q4 results miss estimates
Analysts at domestic brokerage Motilal Oswal Financial Services said the earnings miss was due to a higher tax rate .
Neutral Zydus LifeSciences; target of Rs 1080: Motilal Oswal
Motilal Oswal recommended Neutral rating on Zydus LifeSciences with a target price of Rs 1080 in its research report dated May 20, 2026.
Neutral Blue Star; target of Rs 1920: Motilal Oswal
Motilal Oswal recommended Neutral rating on Blue Star with a target price of Rs 1920 in its research report dated May 07, 2026.
Buy Ajanta Pharma; target of Rs 3400: Motilal Oswal
Motilal Oswal is bullish on Ajanta Pharma has recommended buy rating on the stock with a target price of Rs 3400 in its research report dated May 05, 2026.
Buy Niva Bupa Health Insurance; target of Rs 100: Motilal Oswal
Motilal Oswal recommended is bullish on Niva Bupa Health Insurance recommended buy rating on the stock with a target price of Rs 100 in its research report dated Jun 19, 2026.
Buy Laurus Labs; target of Rs 1370: Motilal Oswal
Motilal Oswal is bullish on Laurus Labs has recommended buy rating on the stock with a target price of Rs 1370 in its research report dated April 30, 2026.
Nifty Pharma jumps nearly 2%; Dr Reddy's, Sun Pharma and Cipla lead gains, dominate Nifty gainers list
Pharma stocks led the gains on benchmark Nifty 50 and the BSE Midcap index on Tuesday. Dr Reddy's, Sun Pharma and Cipla were the top 3 Nifty gainers, amid news reports that the US FDA has asked Indian firms to help address a shortage of ifosfamide injection.
Buy Five Star Business Finance; target of Rs 600: Motilal Oswal
Motilal Oswal recommended is bullish on Five Star Business Finance recommended buy rating on the stock with a target price of Rs 600 in its research report dated Jun 22, 2026.
Neutral Indegene; target of Rs 552: Motilal Oswal
Motilal Oswal recommended Neutral rating on Indegene with a target price of Rs 552 in its research report dated May 02, 2026.
Buy Five Star Business Finance; target of Rs 600: Motilal Oswal
Motilal Oswal is bullish on Five Star Business Finance has recommended buy rating on the stock with a target price of Rs 600 in its research report dated April 29, 2026.